Evidence map›Paper›PMID 41749820›Full record

ArticleCancers2026

Disparities in Tumor Microenvironment Between Primary and Metastatic Colorectal Cancer: Impact on Immune Infiltration and Survival.

Ewelina Dziąg-Dudek, Aleksandra Semeniuk-Wojtaś, Magdalena Modzelewska, Arkadiusz Lubas, Letycja Róg, Barbara Górnicka, Rafał Stec

Abstract read
In one paragraph

Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ewelina Dziąg-DudekOncology Department, Medical University of Warsaw, 02-097 Warsaw, Poland.
Aleksandra Semeniuk-WojtaśOncology Department, Medical University of Warsaw, 02-097 Warsaw, Poland.ORCID 0000-0001-9421-6694
Magdalena ModzelewskaPathomorphology Department, Medical University of Warsaw, 02-097 Warsaw, Poland.
Arkadiusz LubasDepartment of Internal Medicine, Nephrology and Dialysis, Military Institute of Medicine-National Research Institute, 04-141 Warsaw, Poland.ORCID 0000-0002-3248-4615
Letycja RógOncology Department, Medical University of Warsaw, 02-097 Warsaw, Poland.
Barbara GórnickaPathomorphology Department, Medical University of Warsaw, 02-097 Warsaw, Poland.
Rafał StecOncology Department, Medical University of Warsaw, 02-097 Warsaw, Poland.

Funding

Medical University of Warsaw AKBE/142/2021
6 · The paper itself

Abstract

BACKGROUND/

objectivesIn recent years, growing evidence that the tumor microenvironment (TME) plays crucial roles in the progression and treatment responses of various cancers has emerged. Unfortunately, we still do not fully understand the mechanisms through which the TME influences cancer development. Therefore, the aim of this study is to assess the impact of the TME on the clinical course of the disease, comparing primary and metastatic tumors. MATERIALS AND

methodsThis retrospective study included 30 colorectal cancer patients for which tissue samples from primary and metastatic tumors were available for immunohistochemistry. A multiple Cox proportional hazards regression analysis was performed to characterize differences between the microenvironments of primary and metastatic tumors, as well as between lesions diagnosed at different times after resection.

resultsImmune cell infiltration was higher in metastatic than primary tumors. Statistically significant differences were observed only in the central part of the tumor, while cell infiltration at the periphery had no prognostic significance. In the multivariate analysis, a positive correlation was revealed between the expression of Programmed Death-Ligand 1 (PD-L1) on primary tumor cells (TCs) and survival (HR: 5.43; 95% CI: 1.89-15.61;

conclusionsPrimary and metastatic tumors differ regarding their tumor microenvironment. As such, the tumor immune status should be considered as a key factor when selecting a therapeutic strategy, as well as for post-treatment surveillance.

Indexed as

CD68CD8colorectal cancerimmune cellsmetastasesPD-L1tumor microenvironment

Identifiers

PMID41749820
PMCPMC12938962

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.